| Sign In to gain access to subscriptions and/or personal tools. |
DOI: 10.1177/1073858405275177
GM1 Ganglioside and the Seeding of Amyloid in Alzheimer’s Disease: Endogenous Seed for Alzheimer AmyloidDepartment of Alzheimer’s Disease Research, National Institute for Longevity Sciences, National Center for Geriatrics and Gerontology, Obu, Japan, katuhiko{at}nils.go.jp A fundamental question about the pathogenesis of Alzheimer’s disease (AD) is how monomeric, nontoxic amyloid ß-protein (Aß) is converted to its toxic aggregates in the brain. The author previously identified a unique Aß species in the AD brain, which is characterized by its binding to GM1 ganglioside (GM1). On the basis of the molecular characteristics of GM1-bound Aß (GAß), the author hypothesized that GM1 plays a critical role in the process. The author recently examined this possibility using a novel monoclonal antibody raised against purified GAß and validated that GAß is endogenously generated in the brain and accelerates Aß assembly by acting as a seed. Furthermore, the author provided a possibility that aging and the expression of apolipoprotein E4 facilitate Aß assembly in the brain through an increase in the GM1 content in the neuronal membranes, which likely induces GAß generation. The author’s results imply a mechanism underlying the onset of AD and also provide a new insight into development of novel therapeutic strategy.
Key Words: Alzheimer’s disease • Amyloid ß-protein • Seed • Ganglioside • Cholesterol
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
|
Sign In to gain access to subscriptions and/or personal tools.
